Skip to content
Research archive

Research Articles

Randomized Controlled Trial

Cumulative incidence of advanced breast cancer in women aged 40-49 years in the Japan Strategic Anti-cancer Randomised Trial (J-START) of adjunctive ultrasonography: a prespecified secondary analysis.

Adjunctive Ultrasonography Reduces Advanced Breast Cancer Incidence in Women Aged 40–49 — Over a median follow-up exceeding 11 years, adding ultrasonography to mammography screening was associated with about a 17% lower risk of advanced breast cancer in women aged 40–49 compared with mammography alone (HR 0.

Mar 6, 2026 · Lancet · Oncology
66
Randomized Controlled Trial

PA- versus urologist-performed flexible cystoscopy: A comparative study.

PA-Performed Flexible Cystoscopy Matches Urologist Results in Pain and Cancer Detection — Physician associates performing flexible cystoscopy produced virtually identical patient-reported pain scores and bladder cancer detection rates compared to staff urologists, with mean pain scores of 2.

Mar 6, 2026 · JAAPA · Oncology
67
Randomized Controlled Trial

A randomized, double-blind, placebo-controlled trial of olanzapine versus placebo plus ondansetron and dexamethasone for antiemetic prophylaxis in patients receiving oxaliplatin-, irinotecan-, or carboplatin-based chemotherapy.

Low-Dose Olanzapine Significantly Improves Nausea Control With Moderately Emetogenic Chemotherapy — In a randomized, double-blind trial of 139 patients receiving moderately emetogenic chemotherapy, adding 5 mg olanzapine to ondansetron and dexamethasone significantly improved total control of nausea and vomiting compared with placebo (62.

Mar 5, 2026 · Support Care Cancer · Oncology
82
Randomized Controlled Trial

Randomized controlled trial: Synergistic effect of three-ball mindfulness breathing rehabilitation training following pulmonary lobectomy for lung cancer.

Three-Ball Mindfulness Breathing Training Improves Recovery After Lung Cancer Lobectomy — Adding structured three-ball mindfulness breathing exercises to standard pulmonary rehabilitation after lung cancer lobectomy produced measurably shorter hospital stays, reduced dyspnea scores, better exercise tolerance, and lower fatigue and psychological distress compared with conventional rehabilitation alone.

Mar 5, 2026 · Support Care Cancer · Oncology
76
Randomized Controlled Trial

Effects of time-restricted eating on blood pressure in children: A cluster randomized controlled trial.

12-Hour Eating Window Before 8 PM Reduces Blood Pressure in Children Over 12 Months — A cluster-randomized trial found that a 12-hour time-restricted eating window with the last meal completed before 8 PM was associated with a systolic blood pressure reduction of approximately 7 mmHg over 12 months in children and adolescents with elevated blood pressure (-7.

Mar 5, 2026 · Clin Exp Hypertens · Cardiology
75
Randomized Controlled Trial

Effect of percutaneous coronary intervention for chronic total occlusion on diastolic atrioventricular coupling in ST-elevation myocardial infarction patients.

CTO Revascularisation Does Not Improve Diastolic Coupling After STEMI — Among STEMI patients with a concurrent chronic total occlusion, percutaneous coronary intervention of the occluded vessel had no effect on the left atrioventricular coupling index at four months or on its trajectory over time.

Mar 4, 2026 · Int J Cardiol · Cardiology
88
Clinical Trial

High-intensity versus very-high-intensity statin, both on top of ezetimibe, in acute myocardial infarction: A pragmatic randomized study.

Very High-Intensity Statin Plus Ezetimibe Offers Marginal LDL Benefit With More Intolerance Post-AMI — In a randomized trial of 220 acute myocardial infarction patients, very high-intensity statin combined with ezetimibe did not significantly outperform high-intensity statin plus ezetimibe on the composite LDL-C target (63% vs 52%, p = 0.

Mar 4, 2026 · Int J Cardiol · Cardiology
75
Clinical Trial

Safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of a novel anti-TSLP bispecific antibody (GR2002) in healthy Chinese adults: A randomized, placebo-controlled phase 1 trial.

Anti-TSLP Bispecific Antibody GR2002 Shows Favorable Safety and Linear Pharmacokinetics in Phase 1 Trial — A single subcutaneous dose of GR2002 across five escalating doses (35–420 mg) was well tolerated in healthy Chinese adults, with adverse event rates comparable to placebo and no dose-dependent toxicity signal.

Mar 4, 2026 · Eur J Pharm Sci · Immunology
75